administration of recombinant human superoxide dismutase (h-SOD) beginning at the time of postischemic reperfusion enhanced recovery of left ventricular function, improved high-energy phosphate metabolism measured by`P nuclear magnetic resonance in bufferperfused hearts,9 and decreased oxygen free radical generation in vivo.10 Subsequently, Ambrosio et al"l demonstrated a 36% reduction in infarct size when h-SOD was administered as a bolus followed by a 60-minute infusion in a regionally ischemic canine model. On the basis of these data as well as encouraging results obtained in intact regionally ischemic canine and porcine models by several other investigators,'2-14 we designed a multicenter, randomized, placebo-controlled clinical trial to test the hypothesis that reperfusion injury copld be reduced by administration of h-SOD at the time of reperfusion in a population of patients with acute myocardial infarction undergoing early percutaneous transluminal coronary angioplasty (PTCA). PTCA was chosen as the method of reperfusion because it would allow us to document the presence of a total occlusion of the infarct-related artery before reperfusion and also ensure a high concentration of h-SOD at the time of reperfusion. Because of the previously demonstrated mortality benefit of intravenous thrombolytic therapy,3 we allowed intravenous thrombolytics to be administered in the emergency room. The primary end points of this trial were recovery of global and regional left ventricular function, as assessed by paired contrast left ventriculograms and/or paired radionucide ventriculograms. A secondary end point was the frequency of reperfusion-induced arrhythmias.
Methods Patient Population
Patients presenting with at least 20 minutes of chest pain unrelieved by sublingual nitroglycerin and ST segment elevations of at least 0.1 mV in two adjacent ECG leads compatible with an acute transmural infarction underwent coronary angiography to document either total occlusion (TIMI grade 0) or dye penetration of fresh clot without distal opacification (TIMI grade 1). One hundred twenty patients with a totally occluded infarct-related artery (IRA) that could be expected to be reopened by PTCA within 6 hours of the onset of symptoms were entered into a multicenter, randomized, double-blind, placebo-controlled study. All patients were <76 years of age and gave written informed consent for a research protocol that had been approved by each study center's institutional review board.
Exclusion criteria included >50% left main stenosis, indeterminate IRA, evidence of previous transmural infarction in the acutely ischemic region, cardiogenic shock, or severe renal insufficiency. Patients without standard contraindications could have received intravenous thrombolytic therapy before their qualifying coronary angiogram.
Experimental Protocol
After baseline coronary angiography, baseline global and regional left ventricular function was assessed by contrast left ventriculography in the 300 right anterior oblique projection with nonionic contrast media. Before manipulation of the guide wire, 10 mg/kg of recombinant h-SOD or a colormatched placebo solution was injected intravenously as a bolus over 1 minute followed by a 60-minute infusion of 0.2 mg . kg.* min`or placebo equivalent into a peripheral vein. The recombinant h-SOD was expressed in Escherichia coli and supplied by Biotechnology General Corp.
All patients received intravenous heparin 5000 to 10 000 U after arterial access had been obtained, and an intravenous infusion of heparin was maintained for at least 24 hours at a dose sufficient to maintain the partial thromboplastin time at 2 to 2.5 times control. Prophylactic lidocaine therapy was begun before attempted reperfusion with a 1-to 3-mg/kg bolus followed by a 1-to 4-mg/min infusion for at least 24 hours. The infusion rate of lidocaine could be increased or additional antiarrhythmic agents could be added if complex ventricular ectopy was observed. Intravenous nitroglycerin could be administered during the first 12 hours. Oxygen by nasal cannula and analgesics as necessary were routine. Subsequent episodes of ischemic chest pain and/or congestive heart failure were managed as clinically indicated. ,-Blockers were allowed but were to be tapered off, if possible, before follow-up assessments of left ventricular function. If recurrent chest pain or ischemic ECG changes suggested reocclusion, a repeat coronary angiogram was performed and repeat PTCA could be performed if the lesion remained suitable.
A Holter monitor recording was begun as soon as possible after study entry and continued for the ensuing 24 hours. Within 24 hours of study entry, patients underwent a radionuclide ventriculogram in the anterior, 600 left anterior oblique, and lateral views to provide a baseline for a follow-up study performed 4 to 6 weeks later. A second cardiac catheterization was performed 6 to 10 days later in those patients who had successful reperfusion.
Methods of Data Acquisition and Analysis

Contrast Left Ventriculographic Studies
Left ventriculograms acquired in the 30°right anterior oblique view were assessed quantitatively in a core laboratory for global left ventricular ejection fraction and for regional wall motion abnormality by the method of Sheehan et al. 15 Regional function of the infarct zone and the contralateral noninfarct zone was analyzed with the centerline chord method and expressed as SD units compared with normal wall motion. Pretreatment and 6-to 10-day follow-up left ventriculograms were analyzed blindly and independently for motion of each of 100 chords, and wall motion abnormality was expressed in SD per chord.
Radionuclide Ventriculographic Studies
Radionuclide ventriculograms were acquired with a gamma camera (parallel-hole collimator) interfaced to a dedicated computer. Gated blood pool scintigrams were acquired in approximately the 400 left anterior oblique view to best define the interventricular septum. The radionuclide ventriculograms were analyzed in a core laboratory with a Loats Image Analysis System (Loats Inc). Semiautomatic regions of interest were generated over the left ventricle for each frame of the cardiac cycle with a combined second derivative and count threshold algorithm. A background region was automatically generated lateral and inferior to the left ventricle in the end-systolic frame. From these regions of interest, a background-corrected left ventricular time-activity curve was obtained and global left ventricular ejection fraction was calculated. Regional ejection fraction (240 sectors) was assessed quantitatively in the portion of the left ventricle that initially showed the most abnormal motion as well as the best contracting region outside the ischemic zone. These same regions were analyzed again on the 4-to 6-week study to determine changes in regional function.
Twenty-four-Hour Holter Electrocardiographic Recordings
The Holter monitor recordings were read blindly by a trained technician using an electroscanner (Medilog Excel ECG Analysis System, Oxford Medical Ltd) at a scanning speed of 60 times normal. Arrhythmias were printed at a paper speed of 25 mm/s, and the nature of the arrhythmias was confirmed without knowledge of patient assignment. Total numbers of premature ventricular contractions (PVCs) and the incidence and frequency of episodes of (1) ventricular tachycardia (VT) (more than three consecutive PVCs), (2) accelerated idioventricular rhythm (AIVR) (multiple ventricular ectopic beats at a rate of 60 to 100 beats per minute), and (3) bradyarrhythmias (defined as sinus, nodal, or wide complex rhythms at a rate of <60 beats per minute) were tabulated in 10-minute intervals beginning 10 minutes before the time of first balloon deflation (time zero) through the first 60 minutes of reperfusion.
Statistical Analyses
All results are expressed as mean±SD. The two-tailed Student's t test, x2, and one-way ANOVA were used for statistical analysis. The initial sample size for this study was calculated to be 170 patients to have a power of 90%, if the true effect of h-SOD on change in global ejection fraction was an increase of 5 absolute percent over placebo, using a two-tailed t test with a=.05 and an SD of 10%. In addition to an intention-to-treat analysis, which included all randomized patients, a primary efficacy analysis was also carried out, which included only those patients with initially successful PTCA, with an open IRA on the day 6 to 10 angiogram, and with technically adequate paired left ventriculograms and/or gated blood pool scintigrams. The study was terminated after 120 patients were randomized, when a planned interim analysis determined that entering an additional 50 patients would be unlikely to result in a significant change in the primary outcome variables (change in global and/or regional ejection fraction) in favor of h-SOD treatment.
Results
Baseline Characteristics
There were no significant differences in baseline historical, risk factor, or demographic parameters between h-SOD and placebo patient groups for the entire population of 120 randomized patients included in the overall intention-to-treat analysis (Table 1) or for the 71 patients included in the primary efficacy analysis with paired left ventriculograms (55 patients) or paired radionuclide scans (40 patients).
Clinical Outcomes
One hundred twenty patients were randomized: 61 to h-SOD and 59 to placebo. Fourteen of the 120 patients (12%) were not successfully reperfused (9 h-SOD and 5 placebo). The in-hospital mortality was 21% among the 14 patients not successfully reperfused (2 h-SOD and 1 placebo). Among the 106 patients who were successfully reperfused, the in-hospital mortality was 4.8% (2 h-SOD and 3 placebo). No additional deaths occurred between hospital discharge and the 4-to 6-week followup. Fifteen patients required repeat PTCA during hospital admission (6 h-SOD and 9 placebo), and 2 patients (one in each group) required repeat PTCA during the 4-to 6-week follow-up period for clinical indications. Eleven patients required urgent coronary artery bypass surgery during hospital admission (6 h-SOD and 5 placebo), 2 not having been successfully reperfused and 4 found to have a nonpatent IRA on the follow-up angiogram. Three additional patients (1 h-SOD and 2 placebo) underwent coronary artery bypass graft surgery during the ensuing 4 to 6 weeks, again for clinical indications, all having had patent IRAs on the follow-up angiogram. The combined incidence of death or mechanical intervention before the 4-to 6-week follow-up was 29 (Table 2) .
Both the placebo and the h-SOD groups showed improvement in global ejection fraction between the baseline and the predischarge contrast left ventriculograms, +4.4±8.8% for placebo (P<.05 versus baseline) and +1.8±8.7% for h-SOD patients (P=NS versus baseline and P=NS versus placebo) for the 55 patients included in the primary efficacy analysis ( Table 2) .
As with global ejection fraction, there were no differences in mean baseline regional left ventricular wall motion either for all randomized patients or for the subgroups included in the primary efficacy analysis. Improvement in regional ejection fraction was again noted in both groups: +0.92±1.35 SD per chord for placebo (P<.05 versus baseline, P=NS versus h-SOD) and +0.44±0.80 SD per chord for h-SOD patients (P=NS versus baseline) for the 55 patients included in the primary efficacy analysis (Table 2) .
Two predefined subgroup analyses were performed: anterior versus inferior location of the infarct (Table 3) and early (<4 hours from symptom onset) versus late (4 to 6 hours) reperfusion ( cally adequate Holter data beginning at least 10 minutes before time zero. Runs of VT, AIVR, and bradycardia were most frequent during the first two 10-minute periods after reperfusion ("early reperfusion period"). Runs of VT during the early reperfusion period were noted in 10 patients (6 placebo and 4 h-SOD), AIVR in 14 patients (9 placebo and 5 h-SOD), and bradycardia in 16 patients (8 placebo and 8 h-SOD) (P=NS). The incidence of each of these three classes of arrhythmias was consistently lower during the subsequent two 20-minute periods.
Among the 10 patients showing VT during early reperfusion, the number of runs of VT was greater in the placebo group (32) than in the h-SOD group (4 
Discussion
As we observed with placebo treatment in the present study, previous clinical trials that achieved reperfusion with intracoronary or intravenous thrombolytic agents have revealed disappointingly small (in the vicinity of 5%) improvement in global ejection fraction, compared with no change or a small decrease in global ejection fraction in patients not reperfused.16 It had been suggested that the relatively small improvement in global ejection fraction observed with early reperfusion might be due to reperfusion injury subtracting from the expected benefit obtained by termination of the ischemic insult. The present study was the first trial in humans to test the hypothesis that the oxygen free radical scavenger h-SOD would exert a beneficial effect on the recovery of left ventricular function after acute myocardial infarction. The results of the present study failed to show significant improvement in the recovery of global or regional left ventricular function with h-SOD treatment compared with placebo in patients with acute myocardial infarction successfully reperfused by emergency PTCA.
Studies of SOD in animal models of myocardial infarction have yielded conflicting results that are difficult to reconcile.11-'4,17-21 Possible explanations for the negative results include varying durations of ischemia and varying doses and durations of SOD treatment. A coronary occlusion that is brief may provide an inadequate ischemic insult to stimulate the mechanisms of reperfusion injury, whereas an occlusion that is prolonged may cause extensive irreversible ischemic injury, leaving few surviving cells to be affected by subsequent reperfusion injury. It could also be argued that the duration of treatment was too short in several of the negative studies.
The current "gold standard" for quantitative analysis of regional wall motion abnormalities on left ventriculograms is the method of Sheehan et al. 15 Their method was designed to optimize specificity for the detection of abnormal wall motion and not to optimize sensitivity for detecting a change in the function of an individual myocardial segment on two serial left ventriculograms obtained before and after a therapeutic intervention. The presence of myocardial stunning may also complicate the assessment of recovery of left ventricular function after reperfusion of a severely ischemic myocardial segment.22 Radionuclide left ventriculograms were obtained 4 to 6 weeks after myocardial infarction because we were concerned that myocardial stunning might still be present 6 to 10 days after reperfusion. The lack of further improvement in left ventricular function between the contrast left ventriculogram performed on days 6 to 10 and the radionuclide ventriculogram performed 4 to 6 weeks later suggests that stunning had resolved by days 6 to 10. On the basis of this finding, future studies of interventions applied at the time of postischemic reperfusion may not require a late assessment of left ventricular function after hospital discharge. Also, the postreperfusion scintigraphic ejection fraction was on average 5% lower than the baseline ejection fraction obtained by contrast ventriculography. Therefore, future studies of interventions applied at the time of postischemic reperfusion may not require a pretreatment measurement of left ventricular function to provide a baseline for follow-up assessment.
In addition to limitations in the currently available methodologies for assessing myocardial preservation in clinical trials, there are several other possible explanations for the failure of the present study to demonstrate significant improvement in recovery of global or regional left ventricular function: (1) the administration of h-SOD may have begun too late, not allowing sufficient time for this large protein molecule to enter the interstitial and/or the intracellular spaces, which are additional potential sites of free radical generation; (2) the duration of treatment may have been too short to allow scavenging of free radicals generated by neutrophilmediated mechanisms, which have been suggested to occur over hours or days after postischemic reperfusion; and (3) the dose of h-SOD used in the present study (22 mg/kg) may have been too high, such that if the dose-response curve to h-SOD were J-shaped, high doses of h-SOD might be ineffective or even increase infarct size. 23, 24 A recent study from McCord's laboratory (Omar and McCord25) demonstrated that 50 minutes of pretreatment with h-SOD (Cu-Zn) was required in an intact rabbit model of regional ischemia/reperfusion for significant concentrations of h-SOD to be measurable in cardiac lymph. It is unknown whether preexisting collateral channels could have allowed h-SOD access to the vascular distribution of the occluded coronary artery, even if h-SOD treatment had been initiated in the emergency room.
The extent of experimental myocardial infarction was not altered by short-term administration of "native" SOD when infarct size was measured 4 days or 1 week after reperfusion.17 20 Treatment with PEG-SOD, which has a prolonged plasma half-life, limited the extent of infarction measured 4 days after reperfusion.26 Thus, the 1-hour duration of h-SOD treatment used in the present study might have been too short to optimally reduce reperfusion injury mediated by free radicals.
That the dose of h-SOD used in the present study might have been too high can be concluded from experimental data that demonstrated that concentrations of h-SOD of 2 and 5 mg/L optimally reduced infarct size in a regionally ischemic rabbit heart, whereas a concentration of 50 mg/L actually increased infarct size.23 To test the possibility that this loss of protection might be due to the weak peroxidase activity of the Cu-Zn form of SOD, the same investigators used human recombinant Mn-SOD, which lacks peroxidase activity. 24 The same bell-shaped dose-response curve was observed with Mn-SOD, suggesting that the lack of protection at higher doses was not due to peroxidase activity. Although the mechanism of this adverse effect is unclear, the rate of generation of hydrogen peroxide from h-SOD may exceed the capability of endogenous catalase and/or glutathione peroxidase to detoxify hydrogen peroxide, or perhaps overscavenging of superoxide might eliminate an important termination step of lipid peroxidation, namely, reaction of the protonated form of superoxide with lipid peroxide radicals.
Our choice of a dose of h-SOD for the present clinical trial was based largely on the positive results that we had previously obtained in a canine model of 90 minutes of regional ischemia followed by reperfusion.'1 This placebo-controlled study demonstrated a 36% reduction in infarct size with a total dose of h-SOD of 10 to 12 mg/kg: 5 mg/kg given as an initial bolus followed by a 1-hour infusion of 5 to 7 mg/kg." A dose of 22 mg/kg was chosen for the present study to allow for the possibility that the dose required in humans to obtain benefit might exceed that which was effective in the animal model. We were also unaware at the time of any studies showing potential negative effects of higher doses of h-SOD.
Reperfusion after a period of regional ischemia has been recognized to induce both ventricular arrhythmias and bradyarrhythmias in both clinical and experimental animal studies. Runs of VT, AIVR, increased frequency of PVCs, sinus bradycardia, and degrees of heart block have been reported in patients having successful reperfusion with intracoronary streptokinase.27-29 Proposed mechanisms for reperfusion-induced arrhythmias include enhanced automaticity caused by early or late afterdepolarizations,30 reentry,31-33 conduction block in specialized conduction tissue, and/or modulated parasystole. 34 Experimental studies have provided evidence that reperfusion-induced arrhythmias are related to free radical generation. Anti-free radical interventions, including SOD, reduced the occurrence of reperfusion arrhythmias, whereas perfusion of hearts with free radical-generating systems increased the incidence of reperfusion-induced arrhythmias. 35 The effect of SOD on reperfusion arrhythmias in anesthetized rats was found to be dose-dependent. Doses of 10 mg/kg reduced the incidence of ventricular fibrillation, the incidence of atrioventricular block, and mortality, whereas higher doses provided little or no antiarrhythmic benefit. 36 Nejima et a117 reported that h-SOD can reduce reperfusion-induced arrhythmias independent of a reduction in infarct size. h-SOD, at a total dose of 16.1 mg/kg, failed to improve recovery of wall thickening in the ischemic zone or to reduce infarct size in the canine heart. In contrast, h-SOD did reduce the frequency of ventricular premature beats after reperfusion, despite the presence of prophylactic lidocaine therapy in both treated and control animals. Likewise, in a small study of 23 patients with acute myocardial infarction successfully reperfused with intravenous TPA or urokinase, Murohara et a137 found that h-SOD did not alter the recovery of regional ejection fraction but did reduce the total number of PVCs during the first 15 minutes of reperfusion. Arrhythmias observed in the present study were insufficient to confirm the existence of an antiarrhythmic effect of h-SOD in patients with acute myocardial infarction.
One of the proposed mechanisms of myocardial free radical generation is the enzyme xanthine oxidase,6,38,39 and experimental studies have demonstrated that xanthine oxidase inhibition limits reperfusion arrhythmias. 40 Although it is unclear whether the human heart contains significant xanthine oxidase activity, [41] [42] [43] 
